Galecto to Participate at Upcoming Investor Conferences
Galecto, Inc. (NASDAQ: GLTO), a biotechnology company focused on fibrosis and cancer treatments, announced participation in two upcoming conferences. The SVB Leerink Healthcare Conference is set for February 16, 2022, at 8:00 am ET, with a live webcast available. The Credit Suisse London Healthcare Conference will take place March 1-4, 2022, featuring one-on-one meetings. Galecto is developing innovative therapies, including a Phase 2b inhaled modulator for idiopathic pulmonary fibrosis.
- None.
- None.
BOSTON, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced that management will be participating virtually at two upcoming conferences. Details for both events are below:
| SVB Leerink Healthcare Conference | |
| Date: | February 16, 2022 |
| Time: | 8:00 am ET |
| Webcast: | Register Here |
| Credit Suisse London Healthcare Conference | |
| Date: | March 1-4, 2022 |
| Format: | Management will be available for one-on-one meetings |
A live webcast of the presentation at SVB Leerink will be available on the "News & Events" section of Galecto’s Investor website at https://ir.galecto.com/news-and-events/events. A replay of the presentation will be available on this same website following the event.
About Galecto
Galecto is a clinical stage company incorporated in the U.S. that is developing small molecule-based inhibitors of galectin-3 (and the galectin family generally) and LOXL2. Galecto has multiple ongoing Phase 2 clinical programs in fibrosis and cancer, including (i) an inhaled galectin-3 modulator (GB0139) in a Phase 2b trial for the treatment of idiopathic pulmonary fibrosis (IPF); (ii) an orally active LOXL2 inhibitor (GB2064) in a Phase 2a trial for the treatment of myelofibrosis; (iii) an orally active galectin-3 inhibitor (GB1211) in a Phase 1b/2a trial in liver cirrhosis and a separate to-be-initiated Phase 2a trial for the treatment of NSCLC in combination with atezolizumab (Tecentriq®).
Galecto intends to use its website as a means of disclosing material non-public information. For regular updates about Galecto, visit www.galecto.com.
For more information, contact:
| Galecto, Inc. | |
| Hans Schambye, CEO Jon Freve, CFO | |
| +45 70 70 52 10 | |
| Investor Relations US | Investor/Media Relations EU |
| Ashley R. Robinson arr@lifesciadvisors.com | Sandya von der Weid svonderweid@lifesciadvisors.com |
| +1 617 430 7577 | +41 78 680 0538 |
FAQ
When is Galecto's presentation at the SVB Leerink Healthcare Conference?
How can I watch Galecto's webcast for the SVB Leerink Healthcare Conference?
What are the dates for the Credit Suisse London Healthcare Conference?
What is Galecto developing for idiopathic pulmonary fibrosis?
What is the stock symbol for Galecto?
